- Home
- STTK vs INBX Comparison
STTK vs INBX Comparison
Compare STTK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- INBX
- Stock Information
- Founded
- STTK 2016
- INBX 2010
- Country
- STTK United States
- INBX United States
- Employees
- STTK N/A
- INBX N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- INBX Health Care
- Exchange
- STTK Nasdaq
- INBX Nasdaq
- Market Cap
- STTK 112.6M
- INBX 430.2M
- IPO Year
- STTK 2020
- INBX 2020
- Fundamental
- Price
- STTK $2.01
- INBX $80.89
- Analyst Decision
- STTK Hold
- INBX Hold
- Analyst Count
- STTK 5
- INBX 2
- Target Price
- STTK $3.00
- INBX N/A
- AVG Volume (30 Days)
- STTK 196.6K
- INBX 724.3K
- Earning Date
- STTK 11-06-2025
- INBX 11-14-2025
- Dividend Yield
- STTK N/A
- INBX N/A
- EPS Growth
- STTK N/A
- INBX N/A
- EPS
- STTK N/A
- INBX N/A
- Revenue
- STTK $1,000,000.00
- INBX $1,400,000.00
- Revenue This Year
- STTK N/A
- INBX $563.00
- Revenue Next Year
- STTK N/A
- INBX $230.77
- P/E Ratio
- STTK N/A
- INBX N/A
- Revenue Growth
- STTK N/A
- INBX N/A
- 52 Week Low
- STTK $0.69
- INBX $10.81
- 52 Week High
- STTK $2.71
- INBX $86.64
- Technical
- Relative Strength Index (RSI)
- STTK 50.71
- INBX 82.88
- Support Level
- STTK $1.86
- INBX $71.00
- Resistance Level
- STTK $2.08
- INBX $86.62
- Average True Range (ATR)
- STTK 0.14
- INBX 7.97
- MACD
- STTK -0.00
- INBX 2.27
- Stochastic Oscillator
- STTK 65.91
- INBX 90.73
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.